Connor Iapoce

Presented at ASRS 2023, results from a posthoc analysis of YOSEMITE/RHINE suggest a potential anti-fibrotic effect of faricimab versus aflibercept in eyes with DME.

Presented at ASRS 2023, results from FARETINA-AMD suggest positive early treatment patterns and outcomes in patients with nAMD initiating faricimab treatment.

Presented at ASRS 2023, study data showed a single, in-office injection of RGX-314 gene therapy may have long-lasting improvements in diabetic retinopathy severity.

Presented at ASRS 2023, additional results from the Pagoda and Pavilion trials suggest a potential benefit of PDS for patients with DME and diabetic retinopathy.

Presented at ASRS 2023, results from the GALE extension study showed crossover to pegcetacoplan treatment from sham stabilized photoreceptor degeneration over 6 months.

A post hoc analysis of YOSEMITE/RHINE presented at ASRS 2023 suggests faricimab is linked to the faster absence of retinal fluid and fewer injections versus aflibercept in eyes with DME.

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.

Presented at ASRS 2023, an analysis of the Portal trial suggests the efficacy and safety of PDS with ranibizumab was maintained over 5 years in patients with nAMD.

Presented at ASRS 2023, results suggest the potential proof-of-concept for the safety, tolerability, and efficacy of UBX1325 in patients with DME.

Dr. Hahn discusses an anchored matching-adjusted indirect comparison in patients with geographic atrophy, suggesting a greater reduction in observed lesion growth with monthly pegcetacoplan versus avacincaptad pegol.

Presented at ASRS 2023, pegcetacoplan injection showed increasing treatment effects over 30 months for patients with geographic atrophy, with a consistent safety profile to previous phase 3 data.

Late-breaking findings at ASRS 2023 suggest daily home OCT imaging is sufficient for remotely monitoring fluid among patients with treatment-naïve nAMD.

Presented at ASRS 2023, the results showed clinically meaningful reductions in anti-VEGF treatment burden at all dose levels of intravitreal 4D-150 in patients with a high anti-VEGF need.

At ASRS 2023, results from the MOSAIC study indicate the substantial burden of geographic atrophy on patients and their caregivers across the United States and Canada.

Presented at ASRS 2023, study data suggest aflibercept 8 mg provided greater therapeutic benefit, an extended injection interval, and equivalent safety versus aflibercept 2 mg in eyes with nAMD.

However, the meta-analysis of patients treated with ranibizumab suggests a similar proportion of patients achieved DME resolution, regardless of baseline DR severity, by month 24.

A cross-sectional analysis of more than 100 countries and regions revealed a statistically significant association between the prevalence of daily soft drink consumption and the prevalence of overweight and obesity.

A new scientific statement indicates lifestyle interventions may change the trajectory of obesity-related cardiovascular risk from onset in childhood to manifestation in adulthood.

The BARI-OPTIMISE randomized clinical trial reports individuals with poor weight loss after metabolic surgery had significantly greater reductions in body weight after treatment with 3.0 mg liraglutide, compared with placebo.

A new analysis suggests the receipt of self-reported heart health counseling at a postpartum visit was stable or slightly declined from 2016 to 2020, despite increases in CVD risk factors.

A meta-analysis of 20 studies suggests a vegetarian diet was associated with significant reductions in LDL-C, HbA1c, and body weight in individuals at high risk of CVDs.

Granted to Tarsus Pharmaceuticals, the approval of lotilaner ophthalmic solution 0.25% marks the first-and-only FDA-approved therapeutic for Demodex blepharitis, a common eyelid disease.

A cross-sectional analysis suggests disparities in statin use for several race–ethnicity–gender groups were not explained by ASCVD severity or structural factors, including socioeconomic status and health insurance.

Days with a combination of a heat wave and high fine particulate matter air pollution may double the risk of a fatal heart attack, says new research.

A combination of baseline factors, early BCVA, and morphologic responses at 3 months only moderately predicted long-term BCVA responses in eyes with nAMD.

Low vision rehabilitation was associated with statistically significant increases in the overall composite score of a vision-related quality of life scale.

A new analysis suggests Black patients with NICM and an ICD had a high risk and burden of arrhythmia, with a lower survival rate, compared with White patients.

However, the analysis suggests young adults with T2D who underwent vitrectomy for PDR had worse final visual acuity and more complications compared to those with T1D.

A new analysis from the American Heart Association found present-day heart failure risk was higher among Black adults who lived in areas historically impacted by redlining.

Based on objective assessments of visual function with habitual correction, both distance and near visual impairment, and contrast sensitivity impairment, were associated with a higher dementia prevalence.